News

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.

02/25/2025

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation.

02/24/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Intra-Cellular Therapies, Inc. (ITCI) a buy, sell, or hold?

Intra-Cellular Therapies, Inc. (ITCI) can sell. Click on Rating Page for detail.

What is Intra-Cellular Therapies, Inc.'s stock price?

The price of Intra-Cellular Therapies, Inc. (ITCI) is 131.87 and it was updated on 2025-04-03 01:01:43.

Is Intra-Cellular Therapies, Inc. (ITCI) overvalued or undervalued?

Currently Intra-Cellular Therapies, Inc. (ITCI) is in undervalued.

News

From:

To:

Show entries

Search:

News
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales. Mon, Feb. 24, 2025
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago. Fri, Feb. 21, 2025
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023 Fri, Feb. 21, 2025
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says. Tue, Jan. 21, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options. Thu, Jan. 16, 2025

Showing 1 to 5 of 5 entries

Previous1Next

Transcripts

Show entries

Search:

Transcipts Data
Intra-Cellular Therapies, Inc. (ITCI) on Q3 2024 Results - Earnings Call Transcript SA Transcripts Wed, Oct. 30, 2024
Intra-Cellular Therapies, Inc. (ITCI) on Q2 2024 Results - Earnings Call Transcript SA Transcripts Wed, Aug. 07, 2024
Intra-Cellular Therapies, Inc. (ITCI) on Q1 2024 Results - Earnings Call Transcript SA Transcripts Tue, May. 07, 2024
Intra-Cellular Therapies, Inc. (ITCI) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Thu, Feb. 22, 2024
Intra-Cellular Therapies, Inc. (ITCI) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Thu, Nov. 02, 2023
Intra-Cellular Therapies, Inc. (ITCI) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Thu, Aug. 03, 2023
Intra-Cellular Therapies, Inc. (ITCI) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Thu, May. 04, 2023
Intra-Cellular Therapies, Inc. (ITCI) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Wed, Mar. 01, 2023
Intra-Cellular Therapies, Inc. (ITCI) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Thu, Nov. 03, 2022
Intra-Cellular Therapies, Inc. (ITCI) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Tue, Aug. 09, 2022

Showing 1 to 10 of 15 entries

Previous1 2Next

SEC Filings

Show entries

Search:

SEC Filings
Intra-Cellular Therapies, Inc. (ITCI) - DEFM14A SEC Filings 02/18/2025
Intra-Cellular Therapies, Inc. (ITCI) - SCHEDULE 13G/A SEC Filings 02/07/2025
Intra-Cellular Therapies, Inc. (ITCI) - PREM14A SEC Filings 02/05/2025
Intra-Cellular Therapies, Inc. (ITCI) - 4 SEC Filings 02/04/2025
Intra-Cellular Therapies, Inc. (ITCI) - DFAN14A SEC Filings 01/22/2025
Intra-Cellular Therapies, Inc. (ITCI) - DFAN14A SEC Filings 01/13/2025
Intra-Cellular Therapies, Inc. (ITCI) - DEFA14A SEC Filings 01/13/2025
Intra-Cellular Therapies, Inc. (ITCI) - 8-K - Current report SEC Filings 01/13/2025
Intra-Cellular Therapies, Inc. (ITCI) - 8-K - Current report SEC Filings 01/10/2025
Intra-Cellular Therapies, Inc. (ITCI) - 4 SEC Filings 01/03/2025

Showing 1 to 10 of 575 entries

Previous1 2 3 4 5…58Next

Press Releases

Show entries

Search:

StockPrice Release
Intra-cellular therapies investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of intra-cellular therapies, inc. - itci 02/25/2025
Itci stock alert: halper sadeh llc is investigating whether the sale of intra-cellular therapies, inc. is fair to shareholders 02/24/2025
Intra-cellular therapies reports fourth quarter and full-year 2024 financial results 02/21/2025
Shareholder investigation: halper sadeh llc investigates enfn and itci on behalf of shareholders 01/16/2025
Intra-cellular therapies investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of intra-cellular therapies, inc. - itci 01/13/2025
Shareholder alert: ademi llp investigates whether intra-cellular therapies, inc. is obtaining a fair price for its public shareholders 01/13/2025
Itci stock alert: halper sadeh llc is investigating whether the sale of intra-cellular therapies, inc. is fair to shareholders 01/13/2025
Johnson & johnson strengthens neuroscience leadership with acquisition of intra-cellular therapies, inc. 01/13/2025
Johnson & johnson strengthens neuroscience leadership with acquisition of intra-cellular therapies, inc. 01/13/2025
Intra-cellular therapies settles caplyta® (lumateperone) patent litigation with sandoz 01/10/2025

Showing 1 to 10 of 126 entries

Previous1 2 3 4 5…13Next

More Headlines

Show entries

Search:

News
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end. 01/14/2025
Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last? Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. 01/14/2025
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t. 01/13/2025
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Intra-Cellular Therapies stockholders will receive only $132.00 per share in cash. 01/13/2025
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%) 01/13/2025
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040. 01/13/2025
Drugmakers rush to sign deals on first day of industry conference Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco. 01/13/2025
Intra-Cellular just downgraded at Morgan Stanley, here's why Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%) 01/13/2025
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion. 01/13/2025
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation. 01/13/2025

Showing 1 to 10 of 358 entries

Previous1 2 3 4 5…36Next

Unlock

ITCI Ratings Summary

Quant

Strong Sell

ITCI Quant Ranking

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Quant Rating	Strong Sell
Quant Score	1

Is Intra-Cellular Therapies, Inc. (ITCI) a buy, sell, or hold?

What is Intra-Cellular Therapies, Inc.'s stock price?

Is Intra-Cellular Therapies, Inc. (ITCI) overvalued or undervalued?

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Drugmakers rush to sign deals on first day of industry conference

Intra-Cellular just downgraded at Morgan Stanley, here's why

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt